Literature DB >> 5283931

Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone.

M E Celis, S Taleisnik, R Walter.   

Abstract

Microsomal preparations from the stalk median eminence of female rats are shown to contain an enzymic activity that is responsible for the formation of MSH-release-inhibiting factor (MSH-R-IF). The amount of this activity remains constant throughout the estrous cycle. The corresponding mitochondrial preparations from the stalk median eminence contain another enzymic principle, estrous cycle-dependent, which competes with the enzyme present in the microsomal preparation for the same "substrate", and can thereby prevent the formation of MSH-R-IF. Several neurohypophyseal hormones, analogs, and peptide intermediates have been tested for their intrinsic MSH-R-IF activity and for their ability to be transformed into MSH-R-IF by incubation with microsomal preparations of stalk median eminence from male rats; it is concluded that the enzyme responsible for the formation of MSH-R-IF is an exopeptidase and that the release-inhibiting factor itself is a tripeptide. Oxytocin is converted by the incubation to (L)-prolyl-(L)-leucylglycinamide; nanogram amounts of this tripeptide inhibit the release of MSH from the pituitary both in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5283931      PMCID: PMC389210          DOI: 10.1073/pnas.68.7.1428

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Melanocyte-stimulating hormone-releasing and inhibiting factors in two hypothalamic extracts.

Authors:  S Taleisnik; M E Tomatis
Journal:  Endocrinology       Date:  1967-10       Impact factor: 4.736

2.  Antagonistic effect on melanocyte-stimulating hormone release of two neural tissue extracts.

Authors:  S Taleisnik; M E Tomatis
Journal:  Am J Physiol       Date:  1967-01

3.  Effect of hypothalamic lesions on pituitary melanocyte-stimulating hormone.

Authors:  S Taleisnik; J De Olmos; R Orías; M E Tomatis
Journal:  J Endocrinol       Date:  1967-12       Impact factor: 4.286

Review 4.  Automated synthesis of peptides.

Authors:  R B Merrifield
Journal:  Science       Date:  1965-10-08       Impact factor: 47.728

5.  A solid-phase synthesis of [lysine]-vasopressin through a crystalline protected nonapeptide intermediate.

Authors:  J Meienhofer; Y Sano
Journal:  J Am Chem Soc       Date:  1968-05-22       Impact factor: 15.419

6.  Synthesis and some biological properties of 4-valine-oxytocin and 1-deamino-4-valine-oxytocin.

Authors:  V Du Vigneaud; G Flouret; R Walter
Journal:  J Biol Chem       Date:  1966-05-10       Impact factor: 5.157

7.  Activity of neurones in the paraventricular nucleus of the hypothalamus and its control.

Authors:  C M Brooks; T Ishikawa; K Koizumi; H H Lu
Journal:  J Physiol       Date:  1966-01       Impact factor: 5.182

8.  Deamino-oxytocin. Its isolation by partition chromatography on Sephadex and crystallization from water, and its biological activities.

Authors:  B M Ferrier; D Jarvis; V Du Vigneaud
Journal:  J Biol Chem       Date:  1965-11       Impact factor: 5.157

9.  MSH activity in pituitaries of rats treated with hypothalamic extracts.

Authors:  A J Kastin; A V Schally
Journal:  Gen Comp Endocrinol       Date:  1966-12       Impact factor: 2.822

10.  9-Deamidooxytocin, an analog of the hormone containing a glycine residue in place of the glycinamide residue.

Authors:  B M Ferrier; V Du Vigneaud
Journal:  J Med Chem       Date:  1966-01       Impact factor: 7.446

View more
  21 in total

1.  Characterization of melanotropin-release-inhibiting factor (melanostatin) from frog brain: homology with human neuropeptide Y.

Authors:  N Chartrel; J M Conlon; J M Danger; A Fournier; M C Tonon; H Vaudry
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.

Authors:  T Caraceni; E A Parati; F Girotti; I Celano; C Frigerio; D Cocchi; E E Müller
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

3.  Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease.

Authors:  A Barbeau; M Roy; A J Kastin
Journal:  Can Med Assoc J       Date:  1976-01-24       Impact factor: 8.262

4.  Inhibition by Z-Pro-D-Leu of development of tolerance to and physical dependence on morphine in mice.

Authors:  R Walter; R F Ritzmann; H N Bhargava; T C Rainbow; L B Flexner; W A Krivoy
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

5.  Control of the pars intermedia of the lizard, Anolis carolinensis. III. Changes in the ultrastructure of the disconnected neuro-intermediate lobe.

Authors:  L Larsson; E M Rodriguez; P Meurling
Journal:  Cell Tissue Res       Date:  1979-06-08       Impact factor: 5.249

6.  Dissociation of the behavioural and endocrine effects of lysine vasopressin by tryptic digestion.

Authors:  D de Wied; H M Greven; S Lande; A Witter
Journal:  Br J Pharmacol       Date:  1972-05       Impact factor: 8.739

7.  In vitro formation of a MSH-releasing agent by hypothalamic extracts.

Authors:  M E Celis; S Taleisnik
Journal:  Experientia       Date:  1971-12-15

8.  Control of the pars intermedia of the lizard, Anolis carolinensis. V. Extravascular transfer and cellular uptake of horseradish peroxidase in the neuro-intermediate lobe.

Authors:  L Larsson
Journal:  Cell Tissue Res       Date:  1981       Impact factor: 5.249

9.  Control of the pars intermedia of the lizard, Anolis carolinensis. I. Ultrastructure of the intact neural lobe.

Authors:  E M Rodríguez; L Larsson; P Meurling
Journal:  Cell Tissue Res       Date:  1978-01-17       Impact factor: 5.249

10.  The effect of hypothalamic lesions on immuno-reactive alpha-melanocyte stimulating hormone secretion in the rat.

Authors:  R J Penny; F J Tilders; A J Thody
Journal:  J Physiol       Date:  1979-07       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.